-

05:04:47 AM

PRDS Stock News

PRDS - Pardes Biosciences Inc

05/05/23 4:01 PM

Nasdaq : PRDS

earningslow float

Pardes Biosciences Reports First Quarter 2023 Financial Results

Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternatives to maximize

RHEA-AI

negative

04/03/23 8:00 AM

Nasdaq : PRDS

clinical trialcovid-19low float

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors for progression to severe disease experienced

RHEA-AI

neutral

03/14/23 4:01 PM

Nasdaq : PRDS

earningslow float

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Pardes Biosciences, Inc. (NASDAQ: PRDS), a

RHEA-AI

neutral

02/01/23 8:30 AM

Nasdaq : PRDS

conferenceslow float

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of COVID-19, announced that

RHEA-AI

neutral

01/17/23 7:00 AM

Nasdaq : ASMB, PRDS

management

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board. “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Dr. Lopatin completed his training in Internal Medicine at the University of Washington, and New York...

RHEA-AI

very positive

11/07/22 4:01 PM

Nasdaq : PRDS

earningslow float

Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral

RHEA-AI

neutral

11/01/22 8:30 AM

Nasdaq : PRDS

conferenceslow float

Pardes Biosciences to Present at Jefferies London Healthcare Conference

Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and

RHEA-AI

neutral

09/14/22 8:00 AM

Nasdaq : PRDS

managementlow float

Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors

Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and COVID-19

RHEA-AI

very positive

09/13/22 8:00 AM

Nasdaq : PRDS

clinical triallow float

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Pardes Biosciences, Inc. (Nasdaq: PRDS), a

RHEA-AI

neutral

09/12/22 8:30 AM

Nasdaq : PRDS

conferenceslow float

Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and

RHEA-AI

neutral